Liver Cancer Trial, Recruiting NCT06653062 Sponsor: Tongji Hospital Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06653062
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer)
  • People whose liver cancer diagnosis was made following recognised international guidelines for liver cancer management
  • People who have at least one tumour that is large enough to be measured using standard medical imaging criteria
  • People who are expected to live for at least 12 weeks or more
  • People who are willing and able to sign a consent form and attend the required study visits and follow the study procedures

Who may not be able to join:

  • People who have another active cancer or serious medical complications alongside their liver cancer
  • People whose tumour tissue sample is not large enough or suitable enough to be used for a specific type of cancer testing required by the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ze-yang Ding, M.D., Tongji Hospital

Phone: +8613407156200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tongji Hospital
Registry
ClinicalTrials.gov
Start date
18 November 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov